The goal of this Multicentre and international prospective study is to validate a molecular signature using plasma samples in average-risk population for colorectal cancer who undergo colonoscopy in a screening setting. The main question it aims to answer is: Does molecular signature in plasma sample have higher diagnostic accuracy than FIT for early detection of colorectal cancer? Participants who already have a colonoscopy as part of their regular medical care for colorectal cancer screening will provide a stool sample and a plasma sample.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
3,421
Molecular signature using plasma sample
Stool sampling (by the participant)
Colonoscopy will be performed in the course of a screening programme
MVZ für Gastroenterolgie am Bayerischen Platz
Berlin, Germany, Germany
Narodowy Instytut Onkologii w Warszawie Zakład Profilaktyki Nowotworów
Warsaw, Poland, Poland
Demonstrate the diagnosis capacity of molecular signature in plasma samples
Time frame: 48 months
Demonstrate superiority of molecular signature in plasma samples compared with FIT
Time frame: 48 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.